Neumora Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Operating income | -$241.2 | -$263.5 | -$252.1 | -$135.9 | — |
| Net income | -$236.9 | -$243.8 | -$235.9 | -$130.9 | — |
| Balance Sheet | |||||
| Total debt | $60.2 | — | — | — | — |
| Cash Flow Statement | |||||
| Free cash flow | — | — | -$163.4 | -$115.4 | — |
Shares outstanding 187.9M · Free float 29.7%
Annual filing data through FY ended December 31, 2025; float as of September 13, 2026.